Combating resistance to EGFR inhibitors


Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors elicit dramatic initial effects in EGFR-mutant non-small-cell lung cancer (NSCLC), drug resistance commonly develops. Shah et al. modelled acquired resistance in EGFR-mutant lung adenocarcinoma cells, and found that Aurora kinase inhibitors synergistically inhibited cancer cell growth in combination with EGFR inhibitors; findings that were confirmed in mouse and patient-derived xenograft models. In vitro, activation of Aurora kinase A, by its coactivator TPX2, was necessary for acquired resistance and mitigated apoptosis. TPX2 levels were increased in patients with EGFR-mutant NSCLC who had developed erlotinib resistance.


  1. 1

    Shah, K. et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat. Med. (2018).

    Article  Google Scholar 

Download references


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Crunkhorn, S. Combating resistance to EGFR inhibitors. Nat Rev Drug Discov 18, 18 (2019).

Download citation


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing